Clinical Trial Update: Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Rituximab, Yttrium Y-90 ibritumomab tiuxetan, and Melphalan with autologous stem cell transplant in patients with previously treated mu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Melphalan (Melphalan)
• Rituximab (rituximab)
• Yttrium Y-90 ibritumomab tiuxetan (ibritumomab tiuxetan)

Snippet

Sponsor: Mayo Clinic | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 1 | Status: COMPLETED